

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

**兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

### **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 30 March 2022 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2021 and its publication and considering the recommendation on the payment of final dividend, if any.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 18 March 2022

*As at the date of this announcement, the executive director of the Company is Mr. Huang Xiangbin; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*